United States Uterine Fibroid Market Multiply Relentlessly; Asserts MRFR Unleashing Industry Forecast Up To 2030

Rising Awareness and Technological Advancements to Drive the Global Uterine Fibroid Market at a CAGR of 7.92% during the Forecast Period 2025 to 2035

Market Research Future (MRFR) has published a cooked research report on the “Global Uterine Fibroid Market” that contains information from 2025 to 2035. The Uterine Fibroid market is estimated to register a CAGR of 7.92% during the forecast period of 2025 to 2035.

MRFR recognizes the following companies as the key players in the Global Uterine Fibroid Market — Medtronic (US), Boston Scientific (US), Johnson & Johnson (US), Abbott Laboratories (US), Hologic (US), Stryker (US), Bayer (DE), Merck (DE), Ferring Pharmaceuticals (CH), and AstraZeneca (GB).

Market Highlights

The Global Uterine Fibroid Market is accounted for to register a CAGR of 7.92% during the forecast period and is estimated to reach USD 10.41 Billion by 2035.

The Uterine Fibroid Market is witnessing a transformative phase driven by the growing adoption of non-invasive treatment options, advancements in diagnostic technologies, and rising awareness of women’s health issues. Increasing demand for personalized medicine and patient-centric treatment approaches is reshaping the therapeutic landscape.

A key factor fueling market growth is the rising prevalence of uterine fibroids among women of reproductive age, coupled with a growing focus on early diagnosis and effective management strategies. Non-invasive treatment modalities such as MRI-guided focused ultrasound and uterine artery embolization are increasingly preferred due to their shorter recovery times and minimal side effects.

Technological advancements, including the integration of AI-driven diagnostic tools and telehealth platforms, are enhancing accessibility and precision in fibroid detection and treatment. Furthermore, government initiatives, rising healthcare expenditure, and educational programs promoting awareness about reproductive health are expected to boost market expansion globally.

Segment Analysis

The Global Uterine Fibroid Market has been segmented based on Type, Diagnosis, Treatment, and Region.

The Type segment is further bifurcated into Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, and Others. Among these, Intramural Fibroids dominate the market due to their high prevalence and significant impact on women’s health, accounting for a substantial portion of global cases. Conversely, Submucosal Fibroids are the fastest-growing segment, driven by their increasing association with fertility issues and advancements in minimally invasive treatment options.

The Diagnosis segment is divided into Ultrasounds, Magnetic Resonance Imaging (MRI) Scanners, Computed Tomography (CT), and Others.The Ultrasound segment holds the largest market share, owing to its affordability, accessibility, and widespread use as a first-line diagnostic tool. However, MRI scanners are the fastest-growing segment, attributed to their superior imaging accuracy and ability to assess fibroid size, location, and complications in detail.

The Treatment segment comprises Uterine Fibroid Embolization, Magnetic Resonance Guided Focused Ultrasound, Myolysis, Endometrial Ablation, Hysterectomy, and Myomectomy.Uterine Fibroid Embolization dominates the market as a minimally invasive and highly effective treatment option, offering quicker recovery and reduced hospital stays. Meanwhile, Hysterectomy is emerging as the fastest-growing treatment due to improved surgical outcomes and technological advancements in robotic and laparoscopic techniques.

Region Analysis

By Region, the Uterine Fibroid market is segmented into North America, Europe, Asia Pacific, South America, and the Middle East & Africa.

The North America Uterine Fibroid Market holds the largest share, accounting for approximately 45% of the global market. This dominance is attributed to the presence of advanced healthcare infrastructure, growing awareness of uterine health, and strong regulatory support from agencies such as the FDA. The United States leads the region with key players like Medtronic, Boston Scientific, and Johnson & Johnson driving innovation and expanding access to treatment.

Key Findings of the Study

• The Global Uterine Fibroid Market is expected to reach USD 10.41 Billion by 2035, growing at a CAGR of 7.92% during the forecast period.


• North America accounted for the largest market share in 2024 and is projected to maintain its dominance through 2035.


• Asia Pacific is anticipated to be the fastest-growing market for uterine fibroid treatments.


• Based on Type, the Intramural Fibroids segment held the largest share in 2024.


• Based on Treatment, Uterine Fibroid Embolization dominated the market in 2024, while Hysterectomy emerged as the fastest-growing treatment.


• Medtronic (US), Boston Scientific (US), Johnson & Johnson (US), Abbott Laboratories (US), Hologic (US), Stryker (US), Bayer (DE), Merck (DE), Ferring Pharmaceuticals (CH), and AstraZeneca (GB) are identified as the key market players.

Related Reports